Results 71 to 80 of about 39,316 (219)

N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair

Frontiers in Cell and Developmental Biology
Studies have shown that bortezomib resistance in multiple myeloma (MM) is mediated by the abnormalities of various molecules and microenvironments. Exploring these resistance mechanisms will improve the therapeutic efficacy of bortezomib.
Siyi Jiang, Lili Gao, Jian Li, Fangrong Zhang, Yanan Zhang, Jing Liu   +5 more
doaj   +1 more source

Higher proteotoxic stress rather than mitochondrial damage is involved in higher neurotoxicity of bortezomib compared to carfilzomib

Redox Biology, 2020
Proteasome inhibitors have great success for their therapeutic potential against hematologic malignancies. First generation proteasome inhibitor bortezomib induced peripheral neuropathy is considered as a limiting factor in chemotherapy and its second ...
Ayse Tarbin Jannuzzi, Sema Arslan, Ayse Mine Yilmaz, Gulce Sari, Hande Beklen, Lucía Méndez, Maria Fedorova, Kazim Yalcin Arga, Betul Karademir Yilmaz, Buket Alpertunga   +9 more
doaj   +1 more source

Circulating Tumor Cells in Multiple Myeloma: From Peripheral Clues to Central Insights

American Journal of Hematology, EarlyView.
CTC offer a minimally invasive widow into systemic myeloma biology, overcoming the sampling bias of bone marrow biopsies. Their prognostic value at diagnosis, potential role in MRD monitoring, and ability to capture clonal evolution highlight them as actionable biomarkers for future precision medicine.
Benjamin Podvin, Bruno Paiva, Irene M. Ghobrial, Salomon Manier   +3 more
wiley   +1 more source

Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma

Haematologica, 2012
The phase III MMY-3021 study compared safety and efficacy of subcutaneous versus intravenous administration of the proteasome inhibitor bortezomib in patients with relapsed myeloma.
Bertrand Arnulf, Halyna Pylypenko, Sebastian Grosicki, Ievgenii Karamanesht, Xavier Leleu, Helgi van de Velde, Huaibao Feng, Andrew Cakana, William Deraedt, Philippe Moreau   +9 more
doaj   +1 more source

Proliferative glioblastoma cancer cells exhibit persisting temporal control of metabolism and display differential temporal drug susceptibility in chemotherapy [PDF]

, 2019
Even in immortalized cell lines, circadian clocks regulate physiological processes in a time-dependent manner, driving transcriptional and metabolic rhythms, the latter being able to persist without transcription.
Gaveglio, Virginia Lucía, Gorne, Lucas Damián, Guido, Mario Eduardo, Pasquaré, Susana Juana, Salvador, Gabriela Alejandra, Sosa Alderete, Lucas Gastón, Wagner, Paula Micaela   +6 more
core   +1 more source

Drug‐coated balloons: From conventional designs to next‐generation innovations in vascular therapy

BMEMat, EarlyView.
This review traces the evolution of drug‐coated balloons (DCBs) from conventional designs to next‐generation platforms. We highlight innovations in balloon engineering, coating technologies, and therapeutic agents that enhance localized drug delivery while addressing challenges in efficiency, safety, and biocompatibility for vascular and emerging non ...
Lu Zhang, Jiawei Cui, Jin Wang, Manfred F. Maitz, Rifang Luo, Yunbing Wang   +5 more
wiley   +1 more source

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib

Parasites & Vectors, 2009
The proteasome inhibitor and anti-cancer drug bortezomib was tested for in vitro activity against bloodstream forms of Trypanosoma brucei. The concentrations of bortezomib required to reduce the growth rate by 50% and to kill all trypanosomes were 3.3 nM
Wang Xia, Steverding Dietmar
doaj   +1 more source

Proteasome inhibitor bortezomib ameliorates intestinal injury in mice. [PDF]

PLoS ONE, 2012
BACKGROUND: Bortezomib is a proteasome inhibitor that has shown impressive efficacy in the treatment of multiple myeloma. In mice, the addition of dextran sulfate sodium (DSS) to drinking water leads to acute colitis that can serve as an experimental ...
Koichi Yanaba, Yoshihide Asano, Yayoi Tada, Makoto Sugaya, Takafumi Kadono, Shinichi Sato   +5 more
doaj   +1 more source

Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments [PDF]

, 2016
Although adverse effects and glucocorticoid resistance cripple their chronic use, glucocorticoids form the mainstay therapy for acute and chronic inflammatory disorders, and play an important role in treatment protocols of both lymphoid malignancies and ...
Beck, Ilse, Bracke, Marc, Clarisse, Dorien, Offner, Fritz, Sundahl, Nora, Vanden Berghe, Wim   +5 more
core   +2 more sources

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source